Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-09-05
|
MIN-102 ( hydroxypioglitazone -5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride) |
patients with the AMN (adrenomyeloneuropathy) phenotype of X-linked adrenoleukodystrophy (X-ALD) |
2-3 |
Minoryx Therapeutics (Spain) |
Rare diseases - Genetic diseases |
2018-09-05
|
LYS-SAF302 |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
2-3 |
Lysogene (France) |
Rare diseases - Genetic diseases |
2018-09-04
|
BI-1206 and rituximab |
relapsed or refractory non-Hodgkin lymphoma (NHL) including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma |
1-2 |
BioInvent (Sweden) |
Cancer - Oncology |
2018-09-03
|
|
|
|
BioInvent (Sweden) |
Cancer - Oncology - Technology - Services |
2018-08-31
|
anifrolumab |
moderate-to-severe systemic lupus erythematosus (SLE) |
3 |
AstraZeneca (UK) |
Autoimmune diseases |
2018-08-30
|
domagrozumab -PF-06252616 |
Duchenne muscular dystrophy (DMD) |
2 |
Pfizer (USA - NY) |
Genetic diseases - Neuromuscular diseases - Rare diseases |
2018-08-29
|
aducanumab (BIIB037) |
Alzheimer's disease (AD) |
1b |
Biogen (USA - MA) |
Neurodegenerative diseases |
2018-08-28
|
elafibranor - GFT505 |
primary biliary cholangitis (PBC) |
2 |
Genfit (France) |
Liver diseases - Hepatic diseases |
2018-08-27
|
Xarelto® (rivaroxaban) |
patients with chronic heart failure (HF) and significant coronary artery disease (CAD) |
3 |
Bayer HealthCare (Germany) Janssen Research & Development (J&J) (USA - NJ) |
Cardiovascular diseases |
2018-08-24
|
stem cell-derived exosomes |
atopic dermatitis |
preclinical |
Exocobio (Republic of Korea) |
Autoimmune diseases - Dermatological diseases |
2018-08-16
|
fasinumab |
moderate-to-severe osteoarthritis pain of the hip or knee |
3 |
Regeneron Pharmaceuticals (USA - NY) Teva Pharmaceutical (Israel) |
Rheumatic diseases - Inflammatory diseases |
2018-08-16
|
INO-5401, INO-9012 and atezolizumab |
bladder cancer |
1-2a |
Inovio Pharmaceuticals (USA - PA) Roche (Switzerland) |
Cancer - Oncology |
2018-08-16
|
CT-P16 (biosimilar version of bevacizumab - Avastin®) |
breast cancer |
3 |
Celltrion Healthcare (South Korea) |
Cancer - Oncology |
2018-08-16
|
EDIT-101 |
Leber congenital amaurosis type 10 (LCA10) |
1 |
Editas Medicine (USA - MA) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2018-08-15
|
cabotegravir and rilpivirine |
HIV-1 infection |
3 |
ViiV Healthcare (UK - USA) |
Infectious diseases |
2018-08-09
|
Remsima® SC (biosimilar infliximab) |
|
3 |
Celltrion Healthcare (South Korea) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2018-08-09
|
tislelizumab (BGB-A317) |
Stage IIIB or IV squamous non-small cell lung cancer (NSCLC). |
3 |
BeiGene (China) |
Cancer - Oncology |
2018-08-07
|
BL-8040 in combination with G-CSF |
mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients |
3 |
BiolineRX (Israël) |
Cancer - Oncology |
2018-08-07
|
CT-P17 (biosimilar version of Humira® - adalimumab) |
rheumatoid arthritis |
1 |
Celltrion Healthcare (South Korea) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2018-08-07
|
CT-P17 (biosimilar version of Humira® - adalimumab) |
rheumatoid arthritis |
3 |
Celltrion Healthcare (South Korea) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |